These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 21933851)
1. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Klusmann JH; Reinhardt D; Zimmermann M; Kremens B; Vormoor J; Dworzak M; Creutzig U; Klingebiel T Haematologica; 2012 Jan; 97(1):21-9. PubMed ID: 21933851 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438 [TBL] [Abstract][Full Text] [Related]
3. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908 [TBL] [Abstract][Full Text] [Related]
4. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196 [TBL] [Abstract][Full Text] [Related]
5. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512 [TBL] [Abstract][Full Text] [Related]
6. Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. Saraceni F; Labopin M; Gorin NC; Blaise D; Tabrizi R; Volin L; Cornelissen J; Cahn JY; Chevallier P; Craddock C; Wu D; Huynh A; Arcese W; Mohty M; Nagler A; J Hematol Oncol; 2016 Sep; 9(1):79. PubMed ID: 27589849 [TBL] [Abstract][Full Text] [Related]
7. Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Gorin NC; Labopin M; Blaise D; de Groot M; Socié G; Bourhis JH; Ciceri F; Polge E; Nagler A; Mohty M Cancer; 2020 Mar; 126(5):1004-1015. PubMed ID: 31774557 [TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia. Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332 [TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial. Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713 [TBL] [Abstract][Full Text] [Related]
11. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Keating A; DaSilva G; Pérez WS; Gupta V; Cutler CS; Ballen KK; Cairo MS; Camitta BM; Champlin RE; Gajewski JL; Lazarus HM; Lill M; Marks DI; Nabhan C; Schiller GJ; Socie G; Szer J; Tallman MS; Weisdorf DJ Haematologica; 2013 Feb; 98(2):185-92. PubMed ID: 22983587 [TBL] [Abstract][Full Text] [Related]
12. Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Eefting M; von dem Borne PA; de Wreede LC; Halkes CJ; Kersting S; Marijt EW; Veelken H; Falkenburg JF Haematologica; 2014 Apr; 99(4):751-8. PubMed ID: 24241493 [TBL] [Abstract][Full Text] [Related]
13. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920 [TBL] [Abstract][Full Text] [Related]
14. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900 [TBL] [Abstract][Full Text] [Related]
15. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Shimoni A; Labopin M; Savani B; Byrne M; Volin L; Finke J; Niederwieser D; Ehninger G; Blaise D; Beelen D; Tabrizi R; Sengeloev H; Ganser A; Cornelissen JJ; Mohty M; Nagler A Biol Blood Marrow Transplant; 2019 Nov; 25(11):2251-2260. PubMed ID: 31271887 [TBL] [Abstract][Full Text] [Related]
16. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501 [TBL] [Abstract][Full Text] [Related]
18. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. Lee YJ; Baek DW; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Kim HJ; Ham JY; Suh JS; Sohn SK; Moon JH Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e529-e535. PubMed ID: 30268640 [TBL] [Abstract][Full Text] [Related]
19. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: A multi-center study. Zheng FM; Zhang X; Li CF; Cheng YF; Gao L; He YL; Wang Y; Huang XJ Cancer Commun (Lond); 2020 Mar; 40(2-3):93-104. PubMed ID: 32175698 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]